肽受体放射性核素治疗在高分级神经内分泌肿瘤中的系统评价与荟萃分析
该系统评价与荟萃分析纳入截至2025年3月的7项研究共317例G3级胃肠胰神经内分泌肿瘤患者,评估[177Lu]Lu-DOTA-TATE和/或[90Y]Y-SSA的PRRT疗效。汇总客观缓解率为34%(95%CI 22-46),疾病控制率为64%(95%CI 52-76),中位无进展生存期13.88个月,中位总生存期29.95个月。PRRT可能提供可观的疾病控制和缓解率,并似乎能够延缓疾病进展。
要点
- G3级GEP-NEN患者PRRT汇总ORR为34%,DCR为64%。
- 汇总中位PFS为13.88个月,中位OS为29.95个月。
- PRRT可能延缓G3级GEP-NEN疾病进展。
核心结论
- 在G3级胃肠胰神经内分泌肿瘤患者中,PRRT可能提供可观的疾病控制和缓解率,并似乎能够延缓疾病进展。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed和Embase截至2025年3月发表的临床研究,纳入接受[177Lu]Lu-DOTA-TATE和/或[90Y]Y-SSA治疗的G3级GEP-NEN患者,最终分析纳入7项研究共317例患者(范围18至112例)。
主要发现
- 6项研究按RECIST评估288例患者的治疗反应,其中4项研究还按Ki67值进行分层。
- 汇总客观缓解率为34%(95%CI 22-46),疾病控制率为64%(95%CI 52-76)。
- 漏斗图提示这些研究间无发表偏倚。
- 5项研究报告239例患者的中位PFS及95%CI,汇总估计为13.88(95%CI 10.33-18.64)个月。
- 3项研究完整报告174例患者的中位OS及95%CI,汇总估计为29.95(95%CI 19.80-45.30)个月。
关键数值与推荐
- 疗效评估采用RECIST 1.1版,分为完全缓解、部分缓解、稳定疾病和进展疾病。
- 主要结局为客观缓解率和疾病控制率;纳入研究需报告RECIST反应、中位PFS(含95%CI)或中位OS(含95%CI)中至少一项。
临床怎么用
- 对于G3级GEP-NEN患者,PRRT可作为提供疾病控制和延缓进展的治疗选择之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We performed a systematic review and meta-analysis to investigate the efficacy of peptide receptor radionuclide therapy (PRRT) by using radiolabeled somatostatin analogues in high grade gastro-entero-pancreatic neoplasms (GEP-NEN). METHODS: All clinical studies published up to March 2025, including patients with grade 3 (G3) GEP-NEN treated with [177Lu] Lu-DOTA-TATE and/or [90Y] Y-SSA, were identified based on systematic searches in the PubMed and Embase databases. Eligible studies had to report at least one of the following outcomes: 1) response to therapy evaluated according to RECIST (version 1.1 as complete response, partial response, stable disease, progressive disease; 2) median progression free survival (PFS) with 95% confidence intervals (CI); 3) median overall survival (OS) with 95% CI. Objective response rate (ORR) and disease control rate (DCR) were considered as primary outcomes. RESULTS: The final analysis included 7 studies accounting for a total of 317 patients with G3 disease (ranging from 18 to 112). Six studies evaluated response to therapy according to RECIST in 288 patients, and in 4 of them patients were also stratified according to ki67 values. The pooled ORR and DCR were 34% (95% CI: 22-46) and 64% (95% CI: 52-76), respectively. The funnel plot indicated no publication bias among these studies. Five studies reported in 239 patients median PFS with 95% CI, with a pooled estimate of 13.88 (95% CI: 10.33-18.64) months. Three studies fully reported in 174 patients median OS with 95% CI, with a pooled estimate of 29.95 (95% CI: 19.80-45.30) months. CONCLUSIONS: In patients with G3 GEP-NEN, PRRT may provide substantial disease control and response rates, and it seems able to delay the progression of the disease.
引用
- Zampella E, Piscopo L, Green R, et al. Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2026. PMID: 41483309. doi:10.1007/s00259-025-07726-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。